SterisCare's proton pump inhibitor Panocare 40mg (Pantoprazole 40mg delayed-release tablets) has been formally included in the updated National Essential Medicines List (NEML) 2026, recognising its clinical indispensability in the management of acid-related gastric disorders.
Inclusion on the NEML is a significant regulatory milestone, reflecting the product's established safety, efficacy, and cost-effectiveness relative to existing alternatives.
Implications
- Panocare 40 will now be available across all government hospitals and primary health centres under the National Medicines Programme.
- Public procurement volumes are expected to increase significantly from Q2 FY2026-27.
- Insurance reimbursement status improved under PMJAY (Ayushman Bharat) scheme.
This recognition validates our ongoing investment in high-quality, affordable gastroenterology therapeutics.
Keywords
